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Abstract
Background: Although the roles of p21-activated serine/threonine kinase 1 (PAK1) have been reported in some
neurodegenerative diseases, details regarding neurodegeneration are still limited. Hence, we tried to determine the
role of PAK1 and molecular mechanisms of neuronal death involved in neurodegeneration.
Results: Expression of a dominant-negative form of PAK1 (PAK1H83,86L, K299R, PAK1-DN) decreased the cell viability
and increased cell death induced by oxidative stress. Indeed, oxidative stress decreased the phosphorylation of
PAK1 in neuroblastoma cells, cultured dopamine (DA) neurons, or rat midbrains. PAK1-DN reduced the level of Bcl-2
protein, through an ubiquitin/proteasome-dependent mechanism. The level of Bcl-2 may be regulated by PAK1-ERK
signaling and/or PAK1, directly. Conversely, expression of an active form of PAK1 (PAK1T423E, PAK1-CA) could recover
both loss of DA neurons in the substantia nigra (SN) and behavioral defects in a 6-OHDA-induced hemiparkinsonian
rat model.
Conclusions: Our data suggest that the oxidative stress-induced down-regulation of PAK1 activity could be
involved in the loss of mesencephalic DA neurons through modulation of neuronal death, suggesting a novel role
of PAK1 as a molecular determinant and mechanisms in the pathogenesis of Parkinson’s disease.
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Background
The p21-activated serine/threonine kinase 1 (PAK1) has a
role in a variety of cellular functions like cell motility, cell
cycle, survival, and even death. In cancer cells, PAK has
functional roles in growth, invasion, and metastasis [1–5].
Accordingly, the activity of PAK1 is up-regulated through
protein overexpression or gene amplification in cancer tis-
sues [4, 5]. Although the roles of PAK1 have been widely
studied in a variety of cancers and cancer cells, other roles
of PAK1 still remain to be elucidated [6].
Tumor formation and progression requires changes in
cellular events such as the expression of oncogenes, acti-
vation of anti-apoptotic signaling pathways, and simul-
taneous inactivation of pro-apoptotic signals as well as
of tumor suppressors. Apoptosis (type I cell death), also
known as programmed cell death, is a finely regulated
mechanism initiated by signaling in response to a variety
of stresses cells. Thus, it has important roles in develop-
ment and tissue homeostasis in multicellular organisms.
The susceptibility to apoptotic cell death is dependent
on the relative level of anti-apoptotic proteins of Bcl-2
family members (Bcl-2, Bcl-xL, Mcl-1) to that of pro-
apoptotic proteins of the family (Bad, Bax, Bak, Bok) or
the interaction of each protein. Anti-apoptotic protein
Bcl-2, which acts as a proto-oncogene, is a member of
protective complexes that help to maintain the integrity
of mitochondrial membrane. Pro-apoptotic proteins,
such as Bad and Bax, can bind to Bcl-2. This binding
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inhibits the function of Bcl-2 and induces the release of
pro-apoptotic factors by neutralizing the effects of pro-
apoptotic proteins, and cell death eventually [7–9].
PAK1 affects the activity of pro-apoptotic signals in a
Raf-1 dependent or independent manner. Raf-1 activated
by PAK1 is translocalized to the mitochondria, and then
it phosphorylates Bad, which is a pro-apoptotic protein
[10]. Alternatively, PAK1 directly phosphorylates Bad on
Ser112 and Ser136, inducing inhibition of the interaction
with Bcl-2 or Bcl-xL and subsequently resulting in cell
survival [11].
In the nervous system, dysregulation of PAK signaling
is implicated in neurodegenerative diseases, such as
Alzheimer’s disease (AD) and Huntington’s disease
(HD), and mental retardation [12]. Down-regulation of
PAK1 and PAK3, brain specific forms, has been reported
in AD brain [13]. Also, PAK1 overexpression enhanced
the toxicity in a HD cellular model [14]. Rac-PAK signal-
ing was found to be defective in the mouse model of
Fragile X syndrome, Fmr1-KO mouse, suggesting that
PAK1 might also be involved in the pathogenesis of
mental retardation [15]. In addition, knockout of PAK1
induced defects in brain development [16]. However, up
to now, molecular details involved in Parkinson’s disease
(PD) are limited.
It has been widely thought that cancer or neurodegen-
erative disease may originate from opposite fate of cells,
to death or persistent growth, respectively. As a matter
of fact, some neurodegenerative diseases, such as PD,
have an evident inverse co-morbidity with many cancers
[17]. A certain protein, known as a genetic determinant,
may decide directions of the disease to either cancers or
neurodegenerative diseases according to the cellular
condition in which the determinant is activated or inac-
tivated, or the cell type, whether or not the cells have
the ability to proliferate in response to the same external
stimuli that can induce DNA damage or cell cycle acti-
vation [18]. Even importance of genetic determinants or
molecular determinants in the pathogenesis of such dis-
eases, not much research has been performed.
The contradictory roles of PAK1 in cancers and AD
and in cell survival and cell death suggest the possibility
of PAK as a new molecular determinant whose activity
could determine cell fate. Hence, we examined the role
of PAK1 in neuronal death. Here, we report novel mo-
lecular mechanisms involved in the death of mesenceph-
alic DA neurons mediated by PAK1 and suggest a new
molecular target for a therapeutic agent in PD.
Results
Down-regulation of PAK1 activity increases apoptotic cell
death
In order to determine the role of PAK1 in cell prolifera-
tion and viability, we constructed the cell lines stably
expressing wild-type PAK1 (WT), constitutively active
PAK1 mutant (PAK1-CA, PAK1T423E), dominant-
negative PAK1 mutant (PAK1-DN, PAK1H83,86L, K299R)
[19, 20], or GFP using a neuroblastoma cell line, SH-
SY5Y cell line, lentiviral vector, and fluorescence-
activated cell sorting. The SH-SY5Y cells strongly
expressed endogenous PAK1 (Additional 1: Figure S1).
First, to examine the viability of each cell line, the same
number of cells (1X105 cells) were plated and incubated
for 72 h and the amount of viable cells was measured.
As expected, the expression of PAK1-CA increased the
cell viability to 35 %, but the expression of PAK1-DN de-
creased the cell viability to 35 % compared to that of
GFP-expressing cells (Fig. 1a). In addition, these effects
were recapitulated when cell death was induced by oxi-
dative stress, such as treatment with hydrogen peroxide
(H2O2) or 6-hydroxydopamine (6-OHDA) (Fig. 1b, c).
These data indicate that down-regulation of PAK1 activ-
ity enhances both cell death and vulnerability to oxida-
tive stress. Subsequently, we examined the cell death
mechanism which might be involved in the decrease of
cell viability induced by PAK1-DN expression. At 72 h
after plating, SH-SY5Y cells expressing PAK1 mutants
were subjected to TUNEL staining. Apoptotic cell death
in PAK1-DN-expressing cells was increased by approxi-
mately 118 %, compared to that in GFP-expressing con-
trol cells. On the contrary, apoptotic cell death in PAK1-
CA expressing cells was decreased compared to that in
the control cells, but the difference was not significant.
These results indicate that PAK1 activity could regulate
apoptotic cell death in neuroblastoma cells.
PAK1 is inactivated by oxidative stress
Oxidative stress induces cell death, either necrosis (type 2
cell death) or apoptosis (type 1 cell death), in a variety of
cells. In our experiments, PAK1-DN expression increased
cell death induced by treatment with H2O2 or 6-
hydroxydopamine (6-OHDA), but PAK1-CA expression
decreased cell death (Fig. 1b, c). Hence, we examined
whether oxidative stress can regulate the activity of PAK1.
In order to address this question, we examined the relative
level of phosphorylated PAK1 (p-PAK1) to that of total
PAK1 induced by 50 μM 6-OHDA treatment in SH-SY5Y
cells at several time points. The 9 h-treatment with 6-
OHDA significantly decreased the value of p-PAK1/PAK1
and this reduction was correlated with the reduction in
the of Bcl-2 level (Fig. 2a, b). In addition, the reduction in
the Bcl-2 level was also dependent on post-transcriptional
mechanisms (Additional file 2: Figure S2). The inactiva-
tion of PAK1 by oxidative stress, such as 6-OHDA treat-
ment, was further examined in an animal model. At one
week after 20 μg of 6-OHDA was infused into the stri-
atum of rats, the midbrain regions were isolated and sub-
jected to Western blot analysis for p-PAK1 and PAK1.
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The 6-OHDA treatment significantly decreased the value
of p-PAK1/PAK1 in the midbrains (Fig. 2c, d). Next, in
order to exclude the effects of PAK1 in glial cells, we ex-
amined the level of p-PAK1 in response to 6-OHDA treat-
ment in cultured mesencephalic DA neurons. Consistent
with our previous data, the 6-OHDA treatment decreased
the p-PAK1 level in TH-positive neurons, but it did not
decrease the PAK1 level (Additional file 3: Figure S3).
These results show that phosphorylation of PAK1 is de-
creased by oxidative stress.
PAK1 activity could be recovered by PP2B inhibition
We tried to identify an upstream protein phosphatase (PP)
which has an effect on PAK1 by oxidative stress. In order
to address, the SH-SY5Y cells were treated with 6-OHDA
together with Cantharidic acid for inhibition of PP2A and
PP1, Cypermethrin for inhibition of PP2B, or Okadaic acid
for inhibition of PP2A. The Cypermethrin treatment
blocked the down-regulation of PAK1 activity, suggesting
that PP2B might be an upstream phosphatase of PAK1 in
the signaling induced by oxidative stress (Fig. 3a). Cyclo-
sporin A, a widely used immunosuppressant, is also a
potent inhibitor of PP2B, and it has been reported as a neu-
roprotective agent in experimental models of Parkinsonism
[21]. Hence, in the subsequent experiment, we examined
whether Cyclosporin A or Cypermethrin could rescue the
viability of 6-OHDA treated cells. As expected, both Cyclo-
sporin A and Cypermethrin could significantly rescue cell
viability from oxidative stress (Fig. 3b).
PAK1-DN expression decreases the level of Bcl-2 protein
Previous studies [10, 11] indicate that activation of
PAK1 by IL3 directly or indirectly increase the phos-
phorylation level of Bad, a pro-apoptotic Bcl-2 family
protein, consequently reducing the interaction between
Bad and Bcl-2, and thereby increasing cell survival in
FL5.12 lymphoid progenitor cells. In contrast, the auto-
inhibitory domain of PAK1 (amino acids 83–149) en-
hanced apoptotic cell death [11]. Additionally, the
down-regulation of Bcl-2 level was correlated with the
activity of PAK1 (Fig. 2). Thus, in order to identify the
molecular mechanisms implicated in apoptotic cell death
caused by down-regulation of PAK1 activity, we exam-
ined the level of the members of anti-apoptotic and pro-
Fig. 1 PAK1-DN expression reduces viability. a PAK1-DN expression reduced viability of SH-SY5Y cells but expression of PAK1-CA mutant increased
viability of Sh-SY5Y cells (GFP: 100.0 ± 2.99 %, n = 4; WT: 88.6 ± 2.84 %, n = 4; CA: 135.1 ± 6.03 %, n = 4; DN: 65.94 ± 3.80 %, n = 4; One-way ANOVA, F3,15 =
49.14, ****P< 0.0001, Newman-Keuls multiple comparison test: ***P< 0.001, ns: not significant). b PAK1-DN expression reduced viability of SH-SY5Y cells after
oxidative stress induced by treatment with hydrogen peroxide (GFP: 100.0 ± 2.68 %, n = 12; WT: 138.7 ± 2.13 %, n = 12; CA: 154.1 ± 2.52 %, n = 12; DN:
75.41 ± 2.18 %, n = 12; One-way ANOVA, F3,47 = 225.6,
****P< 0.0001, Newman-Keuls multiple comparison test: ***P< 0.001). c PAK1-DN expression reduced
viability of SH-SY5Y cells after oxidative stress induced by treatment with 6-hydroxydopamine (GFP: 100.0 ± 3.12 %, n = 4; WT: 121.2 ± 5.73 %, n = 4; CA:
161.3 ± 14.11 %, n = 4; DN: 71.35 ± 2.92 %, n = 12; One-way ANOVA, F3,15 = 22.95,
****P< 0.0001, Newman-Keuls multiple comparison test: *P< 0.05,
***P< 0.001, ns: not significant). d PAK1-DN expression significantly increased apoptotic cell death. At 72 h after plating of SH-SY5Y cells expressing PAK1
mutants, the cells were subjected to TUNEL staining. e Bar graphic representation of TUNEL staining results (GFP: 17.6 ± 30.63 %, n = 3; CA: 14.4 ± 3.31 %,
n = 3; DN: 39.08 ± 8.46 %, n = 3; One-way ANOVA, F2,8 = 6.50, P= 0.0315, Newman-Keuls multiple comparison test:
*P< 0.05)
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Fig. 2 Oxidative stress induced by 6-OHDA treatment reduces phosphorylated PAK1. a SH-SY5Y cells were treated with 50 μM of 6-OHDA and
harvested at 0, 3, 6, and 9 h after treatment. The lysates were used to measure phosphorylated PAK1 and total PAK1 levels by Western blot
analysis. b Bar graphic representation of Western blot analysis [0 h: 100.0 ± 11.61 %, n = 3; 3 h: 95.4 ± 5.35 %, n = 3; 6 h: 78.2 ± 10.76, n = 3; 9 h:
36.0 ± 14.19 %, n = 3, One-way ANOVA, F3,11 = 7.070, P = 0.0122, Newman-Keuls multiple comparison test:
*P < 0.05]. c A 4 μl dose of 6-OHDA (5
μg/μl) was infused into the right striatum at rate of 0.5 μl/min. After 7 days, the midbrain regions including the substantia nigra of the ipsilateral
side and contralateral side were isolated and 30 μg of each protein was used for Western blot analysis. d Bar graphic representation of Western
blotting analysis (Contra: 100.0 %, n = 3; Ipsi: 68.2 ± 1.56 %, n = 3, Paired t-tests, ** P < 0.001)
Fig. 3 PP2B inhibitor reverses the down-regulation of PAK1 activity induced by oxidative stress. a SH-SY5Y cells were treated with 50 μM
6-OHDA along with 200 nM Cantharidic acid, 0.2 nM Cypermethrin, or 0.5 nM Okadaic acid for 9 h. The cell lysates were harvested and subjected
to Western blotting. b SH-SY5Y cells were treated with 50 μM 6-OHDA along with 0.5 nM Okadaic acid (Okad), 0.2 nM Cypermethrin (Cyper), or
10 μM Cyclosporin A (CsA) for 9 h and subjected to cell viability assay. Both Cypermethrin and Cyclosporin A treatment significantly blocked cell
death, but Okadaic acid treatment did not block cell death (CTL: 100.0 ± 4.48 %, n = 6; 6-OHDA: 58.0 ± 0.74 %, n = 6; Okad: 37.6 ± 0.69 %, n = 6;
Cyper: 86.6 ± 1.55 %, n = 6; CsA: 67.5 ± 0.90 %, n = 6, One-way ANOVA, F4,29 = 122.3, ****P < 0.0001, Newman-Keuls multiple comparison test:
**P < 0.01, ***P < 0.001)
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apoptotic Bcl-2 family proteins induced by PAK1-DN
expression. As shown in Fig. 4a, Bcl-2 and Bcl-xL, mem-
bers of anti-apoptotic Bcl-2 family proteins, were down-
regulated by the PAK1-DN expression. Also, the down-
regulation of proteins was recapitulated in the transient
expression of PAK1-DN plasmid vector in human em-
bryonic kidney (HEK) 293T cells (Additional file 4:
Figure S4). Consequently, to identify the molecular
mechanisms involved in the down-regulation, we exam-
ined the mRNA levels of Bcl-2 and Bcl-xL by RT-PCR ana-
lysis. Interestingly, the decrease in the protein level by
PAK1-DN expression was not correlated with the level of
each mRNA, suggesting a regulatory mechanism in the
post-translational stage (Additional file 5: Figure S5).
In order to further clarify whether the decrease of Bcl-
2 or Bcl-xL is a specific event regulated by PAK1-DN,
we examined the dose-dependency of Bcl-2 decrease in-
duced by PAK1-DN. The HEK 293T cells were trans-
fected with 1, 1.5, 2, or 3 μg of PAK1-DN plasmids, and
subsequently the protein levels of Bcl-2 or Bcl-xL were
examined. As shown in Fig. 4b, c, the level of Bcl-2 was
inversely correlated with the level of PAK1-DN. The de-
crease in Bcl-xL was only evident in cells transfected
with 3 μg of PAK1-DN plasmids, but it did not show
any dose-dependency. In the subsequent experiments,
we examined the levels of Bcl-2 and Bcl-xL induced by
the expression of PAK1-WT, PAK1-CA, or other
inactive-form mutants (PAK1H83,86L, PAK1K299R, PAK1
67–150 amino acids). No alteration in the Bcl-2 level
was detected, except PAK1K299R or PAK1 67–150 aa ex-
pression. The levels of Bcl-xL induced by transient ex-
pression of PAK1 mutants were not altered in all results,
being different from those induced by stable expression
of PAK1-DN (Additional file 6: Figure S6).
Previous studies have reported that the cellular level of
Bcl-2 is modulated by the ubiquitin/proteasome-
dependent pathway and this degradation is dependent
on the phosphorylation status of Bcl-2, which is
Fig. 4 PAK1-DN expression reduces the Bcl-2 level. a PAK1-DN expression reduces level of anti-apoptotic Bcl-2 family proteins. Lysates of SH-SY5Y cells
expressing GFP, PAK1-CA, or PAK1-DN were subjected to Western Blot analysis using antibodies against anti-apoptotic or pro-apoptotic Bcl-2 family
proteins. b Reduction in Bcl-2 induced by PAK1-DN expression is mediated by ubiquitin-dependent protein degradation. HEK cells were transfected
with 1, 1.5, 2, or 3 μg of PAK1-DN vector and incubated for 36 h and treated with 10 μM lactacystin or without for 12 h. The cell lysates were subjected
to Western blot analyses using the indicated antibodies. c Quantification of Western blot analysis. To obtain relative values of Bcl-2 or Bcl-xL level, band
intensities from 1 and 2 μg expression of PAK1-DN was normalized by that from 3 μg expression of PAK1-DN in each blot. Reduction in Bcl-2 induced
by dose-dependent expression of PAK1-DN reversed by lactacystin treatment [−Lact: 362.68 % (1 μg)→ 182.6 % (2 μg)→ 100.0 % (3 μg), +Lact: 118.5
± 19.26 %, n = 3 (1 μg)→ 109.05 ± 15.10 %, n = 3 (2 μg)→ 100.0 %, n = 3 (3 μg)]. Bcl-xL level was not altered [−Lact: 127.7 % (1 μg)→ 148.4 % (2 μg:)→
100.0 % (3 μg), +Lact: 97.0 ± 13.89 %, n = 3 (1 μg)→ 100.94 ± 12.59 %, n = 3 (2 μg)→ 100.0 %, n = 3 (3 μg)]. d PAK1-DN expression increased the
ubiquitination of Bcl-2 protein, but PAK1-CA expression did not increase the ubiquitination of Bcl-2 protein
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modulated by mitogen-activated protein (MAP) kinase
[22, 23]. Hence, we examined whether the down-
regulation of Bcl-2 by PAK1-DN is dependent on the
ubiquitin/proteasome-dependent pathway. As shown in
Fig. 4b, c, the down-regulation of Bcl-2 level by PAK1-
DN was completely blocked by 10 μM lactacystin, an in-
hibitor of the ubiquitin/proteasome-dependent pathway.
In addition, treatment with MG-132, another specific in-
hibitor to the ubiquitin/proteasome-dependent pathway,
showed the same results (data not shown). Conse-
quently, in the subsequent experiment, we examined the
ubiquitination of Bcl-2 induced by PAK1-DN expression.
Indeed, PAK1-DN expression predominantly increased
the ubiquitination level of Bcl-2 protein (Fig. 4d). These
results suggest that PAK1 activity could modulate the
Bcl-2 level via the ubiquitin/proteasome-dependent
mechanism.
Bcl-2 level could be modulated by both PAK1-MAPK
signaling and PAK1 directly
As previously described, Bcl-2 protein is down-regulated
by the ubiquitin/proteasome-dependent mechanism and
this degradation is dependent on the phosphoryation
status of Bcl-2, which is modulated by the mitogen-
activated protein kinase (MAPK) pathway [22, 23].
Hence, we examined whether the down-regulation of
Bcl-2 by PAK1-DN expression could be rescued by
extracellular signal-regulated kinase (ERK) expression.
As a result, the down-regulation of Bcl-2 by PAK1-DN
expression was recovered by ERK2 expression (Fig. 5a).
In order to further clarify this result, serine 87 on Bcl-2,
which is reported to be a major site for phosphorylation
by MAP kinase, was changed to aspartic acid, mimicking
phosphorylation (Bcl-2S87D, S87D) or an alanine residue
(Bcl-2S87A, S87A). As expected, the level of S87D was
not altered by PAK-DN expression. These results suggest
that the Bcl-2 level could be modulated by the PAK1-
MAPK pathway.
We questioned whether the level of Bcl-2 might be
directly regulated by PAK1. A putative site for phosphor-
ylation by PAK1 on the amino acid sequences of human
Bcl-2 was examined using GPS 2.1.2 (Group-based Pre-
diction system), a kinase-specific prediction program
[24]. Serine 70 was isolated as a putative site for phos-
phorylation by STE20/PAK1. We constructed mutants
in which serine 70 was changed to glutamic acid (Bcl-
2S70E, S70E) or alanine (Bcl-2S70A, S70A), and we exam-
ined the level of each Bcl-2 mutant induced by PAK1-
DN expression. Interestingly, S70E was resistant to the
degradation mediated by PAK1-DN expression (Fig. 5b).
In order to examine the association of PAK1 with Bcl-2,
we performed coimmunoprecipiation (co-IP) assay.
PAK1-CA was associated with Bcl-2 immunecomplexes
and this association was much stronger than that of
PAK1-DN with Bcl-2 immunecomplexes (Fig. 5c).
Taken together, these data suggest that Bcl-2 level
could be modulated by PAK1-MAPK signaling and/or
PAK1 directly.
Fig. 5 Reduction in the Bcl-2 level induced by PAK1-DN is mediated by PAK1-ERK or PAK1 directly. a HEK 293T cells were transfected with 1, 2, or
3 μg of PAK1-DN vectors and with 1 μg of CFP-ERK2 or without CFP-ERK2. Dose-dependent reduction in the Bcl-2 level induced by PAK1-DN was
blocked by ERK2 expression. b Bcl-2S87D (serine 87→ aspartic acid), a phosphomimetic form by ERK was resistant to PAK1-DN expression. Bcl-2S87
(serine 87→ alanine) did not show resistance to PAK1-DN expression. Bcl-2S70E (serine 70→ glutamic acid), a putative phosphomimetic form by
PAK1 was also resistant to PAK1-DN expression. All Bcl-2 mutants were not altered by PAK1-CA expression. c HEK 293T cells were transfected with
FLAG-tagged Bcl-2 and Myc-tagged PAK1-CA or PAK1-DN vectors. The cell lysates were immunoprecipitated with anti-FLAG antibody and the
resulting immunoprecipitates were subjected to Western blot analysis using anti-Myc antibody
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PAK1-CA recovers behavioral and cellular defects in
hemiparkinsonian rat model
The catecholamine neurotoxin, 6-hydroxydopamine (6-
OHDA) has been widely used to PD model [25, 26]. We
examined the effect of PAK1-CA expression on the DA
neuron survival and animal behavior in a 6-OHDA-
induced hemiparkinsonian rat model. In order to induce
progressive death of nigral neurons, 6-OHDA was
injected into the striatum, and subsequently, lenti-
PAK1-CA or lenti-GFP virus was injected into the ipsi-
lateral substantia nigra pars compacta (SNpc) [27, 28].
During 3 weeks, behavioral assay was performed to
examine forelimb-use asymmetry at every week (Fig. 6a)
[25, 29, 30]. Finally, tyrosine hydroxylase (TH)-positive
neurons in the ipsilateral SNpc were measured by com-
paring with TH-positive neurons in the contralateral
SNpc. As shown in Fig. 6b, c, PAK-CA expression in the
substantia nigra significantly blocked the loss of TH-
positive neurons induced by 6-OHDA treatment. Con-
sistent with cellular protection, the PAK1-CA expression
significantly recovered behavioral defects from 2 weeks
after the infusion and infection, compared to those in
the GFP-expressing control group. Additionally, the re-
covery from loss of TH-positive neurons and behavioral
Fig. 6 PAK1-CA expression recovers behavioral defect and loss of mesencephalic dopamine neurons. a Experimental scheme and procedure. b
Lentiviruses encoding GFP or PAK1-CA were infused into the right SNpc at rate of 0.5 μl/min at the following coordinates: anteroposterior, −5.3
mm from the bregma; mediolateral, 2.3 mm; dorsoventral, −7.3 mm below surface of the dura. After 3 weeks, the midbrain tissue sections were
immunostained with anti-Tyrosine Hyroxylase antibody and visualized by immunostaining using Cy3-conjugated goat anti-rabbit IgG antibody. c
The loss of DA neurons in the SNpc induced by 6-OHDA treatment was blocked by PAK1-CA expression, but not by GFP expression (GFP: 79.5 ±
1.55 %, n = 5, compared to the ipsilateral side; PAK1-CA: 88.4 ± 2.94 %, n = 5, compare to ipsilateral side, Student’s t-tests, *P < 0.05). d PAK1-CA
expression significantly improved usage of the contralateral limb in a hemiparkinsonian animal model (GFP: PAK1-CA, pretest, 48.2 ± 1.69, n = 5:
48.08 ± 1.37, n = 8; 1 week, 16.0 ± 4.46, n = 5: 26.00 ± 2.30, n = 8; 2 weeks, 11.7 ± 3.73, n = 5: 26.21 ± 3.58, n = 8; 3 weeks, 7.8 ± 0.93, n = 4: 30.88 ±
4.32, n = 6; Two-way ANOVA, F3,41 = 39.40, ***P < 0.0001, Bonferroni multiple comparison tests, ns: not significant, **P < 0.01, ***P < 0.001)
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defects by the PAK1-CA expression was recapitulated in
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride
(MPTP)-induced hemiparkinsonian rat model (Additional
file 7: Figure S7). These data strongly suggest that the
activity of PAK1 could be related with the survival of
TH-positive neurons and behaviors.
Discussion
Since a very long time, there have been many discussions
on the inverse comorbidity between some cancers and
neurodegenerative diseases [17]. A genetic determinant
can decide the fate of cells, depending on the situations
or the characteristic of cells [18]. Previous studies have
described that overactivation or overexpression of PAK1
is strongly correlated with cancers [4, 5]. In our study,
down-regulation of PAK1 activity, and not amount, was
correlated with cell death and that occurs at the initial
stage of cell death induced by oxidative stress, such as 6-
OHDA treatment (Fig. 1, 2). These results suggest that
PAK1 might function as a molecular determinant that
may decide the direction for development of neurode-
generative diseases, such as Parkinson’s disease (Fig. 7).
It has been widely accepted that apoptosis (type I cell
death) is the major cause of neuronal loss in PD [31].
Some studies, using postmortem brain sections of PD
patients, have reported that loss of the nigral neurons is
due to apoptosis induced by an increase in Bax (a proa-
poptotic member of the Bcl-2 family)-dependent mito-
chondrial membrane permeability [31–33]. If cell fate is
determined by the ratio of pro-apoptotic to anti-
apoptotic proteins, a reduction in Bcl-2 could increase
Bax-triggered apoptosis. Of course, some part of this
apoptotic cell death might originate from dephosphory-
lation of Bad induced by inactivation of PAK signaling
[10, 11]. However, if we consider that the expression of
Bax in the melanized nigral neurons is more related with
PD brains [32, 33], Bax-triggered apoptosis induced by
the reduction in Bcl-2 could be a major pathway. Even
in our conclusion, the possibility that two pathways act
synergistically or simultaneously, cannot be excluded.
Thus, in order to clarify this, more studies are needed.
Unwanted proteins should be cleared by cellular clear-
ance systems. The failure of clearance system could in-
crease the number of misfolded and aggregated proteins.
Thus, the ubiquitin-proteasome system is closely linked
with the development of PD. Indeed, mutations of genes
involved in the ubiquitin-proteasome system are found
in several types of familial PD and proteasomal enzym-
atic activity is reduced in sporadic PD [34]. In our study
(Fig. 2, 3) and previous reports [22, 23], oxidative stress
regulated PAK1 activity. Subsequently, PAK1 could regu-
late the level of Bcl-2 protein through the ubiquitin-
proteasome system by modulating its phosphorylation
status through the extracellular signal-regulated kinase
(ERK) pathway [22, 23]. However, these mechanisms
only work when ubiquitin-proteasome system is intact
or partially working. Protein aggregates, known as Lewy
bodies, in nigral neurons have toxic effects. Production
of protein aggregates might be due to an imbalance be-
tween the amount of unwanted proteins and the cap-
acity to remove them. Indeed, the reduction of removal
capacity is correlated with aging [35, 36].
Extracellular signals that lead to the activation or in-
activation of PAK1 have not been clearly elucidated. In
particular, inactivation mechanisms including dephos-
phorylation mechanisms still remain to be elucidated.
Although PP2A [37, 38], POPX1/2 [39] and PP2Cα [40]
have been reported as PAK1 regulators in different
Fig. 7 Model of PAK1 roles in the pathogenesis of diseases. An oxidative stress might induce activation of a phosphatase for PAK1 or inhibit
phosphorylation of PAK1 via other mechanisms. Consequently, the down-regulation of PAK1 activity decreases the phosphorylation of Bcl-2 and
the dephosphorylated Bcl-2 proteins are to be more susceptible to an ubiquitin/proteasome-dependent degradation. Reduction of Bcl-2 level
induces loss of cells, such as mesencephalic dopamine neurons, thereby inducing Parkinson’s disease (PD)
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cellular contexts, there has been no report on the phos-
phatase for PAK1 in response to oxidative stress. Our
data suggest calcineurin, PP2B, as a phosphatase for
PAK1 in the signaling involved in oxidative stress
(Fig. 3a). Indeed, the inhibitors of PP2B decreased the
death rate of neuroblastoma cells induced by 6-OHDA
treatment (Fig. 3b), suggesting a new target for PD
therapy. For treatment of PD, levodopa (L-dopa), a
dopamine precursor has been widely used. However,
long-term treatment causes some side effects such as
psychiatric symptoms, wearing-off phenomenon, or on/
off phenomenon. The focus of new therapy has been on
the development of agents that suppress or delay neur-
onal death [21]. Cyclosporin A, an immunosuppressant,
has been used to suppress the immune response after
transplantation. Interestingly, treatment of Cyclosporin
A protects cortical neurons from traumatic brain injury
[41, 42] and attenuates the decrease of tyrosine hydroxy-
lase in the nigrostriatal DA neurons and DA neurons it-
self in a 6-OHDA animal model of PD [21]. Our data
also showed that treatment with Cyclosporin A in-
creased the viability of neuroblastoma cells treated with
the neurotoxin, 6-OHDA (Fig. 3). Thus we suggest a
novel molecular mechanism for neuroprotective effects
of Cyclosporin A. Inactivation of PAK1 induced by oxi-
dative stress might be blocked by the inhibition of PP2B
by Cyclosporin A, thereby increasing cell viability (Fig. 7).
However, more studies are required for the clinical ap-
plication of Cyclosporin A in PD patients.
Methods
Experimental animal
Adult female (~230 g) and postnatal 1-day-Sprague–
Dawley rats were purchased from SAMTAKO (Osan,
Korea) for the animal model of Parkinson’s disease and
the culture of dopamine neurons, respectively. All exper-
iments were performed in accordance with the approved
animal protocols and the guidelines of the Institutional
Animal Care and Use Committee of Chungbuk National
University (CBNUA-432-12-02).
Cell culture
Human embryonic kidney (HEK) 293T cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO®,
Grand Island, NY, USA) supplemented with 7–10 % fetal
bovine serum (GIBCO®) and supplied with 5 % CO2, 37 °C.
Human neuroblastoma cells (SH-SY5Y) were grown in Ea-
gle’s Minimum Essential Medium and F12 Medium supple-
mented with 10 % fetal bovine serum (GIBCO®). To obtain
culture of mesencephalic dopamine neurons, astrocytes
were placed on collagen/poly-L-lysine coated coverglass
and incubated for 7 days. Dopamine neurons isolated from
the substantia nigra (SN) and ventral tegmental area (VTA)
of post-natal 1-day-old rats were placed on the astrocyte
monolayer and incubated for 16 days before use [43].
DNA construction and lentivirus
For expression of PAK1 and its mutants, PAK1 wild type
(WT), kinase-active PAK1T423E (PAK1-CA) and dominant-
negative PAK1H83,86L, K299R (PAK1-DN) [44] were inserted
into the pCMV-myc vector (Clontech, Palo Alto, CA,
USA) for cell line expressions, and into the pHJEF1a(sin)
vector for lentiviral expression. For expression of ERK2,
ERK2 was inserted into the pCFP-C1 vector (Clontech),
resulting in pCFP-ERK2. The preparations of lentivirus and
Sindbis virus were performed according to the previously
described methods [45]. Human Bcl-2 mutants (S70E,
S70A, S87D, and S87A) were made by recombinant PCR









To obtain pure cell cultures expressing GFP, PAK1 wild
type (WT), constitutively active PAK1T423E (PAK1-CA)
mutant, or dominant-negative PAK1H83,86L, K299R (PAK1-
DN) mutant, after lentiviral infection of encoding GFP
only or each PAK1 mutant and bicistronically linked
GFP, SH-SY5Y cells were sorted by a fluorescence-
activated cell sorter (FACSCalibur, BD Biosciences,
Franklin Lakes, NJ, USA) using fluorescence of GFP, and
stored.
Cell viability assay and TUNEL staining
For the viability assay, SH-SY5Y cells expressing GFP,
PAK1-WT, PAK1-CA or PAK1-DN, were plated at
1X105 cells per well and incubated for 72 h. For asses-
sing viability following oxidative stress, cells were plated
and incubated for 24 h and additionally incubated with
700 μM hydrogen peroxide (Sigma-Aldrich, St Louis,
MO, USA), 100 μM 6-hydroxydopamine (Sigma-Al-
drich), or without both for 12 h. For the viability assay
after phosphatase inhibitor treatment, SH-SY5Y cells
(1X105 cells) were pretreated with 0.2 nM Cypermethrin
(Santa Cruz, Santa Cruz, CA, USA), 0.5 nM Okadaic
acid (Sigma-Aldrich), or 10 μM Cyclosporin A (Tocris,
Bristol Avonmouth, UK) for 30 min and subsequently
treated along with 50 μM 6-OHDA for 8 h 30 min. The
number of viable cells was determined by colorimetric
assay using WST-8 (Dojindo Laboratories, Kumamoto,
Japan). To measure apoptotic cell death, at 72 h after
cell plating, cultures were subjected to TUNEL staining
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using In Situ Cell Death Detection kit (Roche, Basel,
Switzerland). The apoptosis rates were determined by
the number of TUNEL-positive cells in that of GFP-
positive cells on three culture dishes for each condition.
Western blotting
SH-SY5Y cells expressing GFP, PAK1-CA, or PAK1-DN
were plated and incubated for 72 h. The cultured HEK
293T cells were transfected with the indicated plasmids
and GFP vector, thus making up the total amount of
plasmids used in transfection to 3 μg, and were incu-
bated 48 h to induce expression. For lactacystin (Tocris)
treatment, after 36 h of incubation, transfected cells
were treated with 10 μM lactacystin for 12 h. For West-
ern blot analysis, the lysates of cells were prepared by
adding the lysis buffer (150 mM NaCl, 1 % IGEPAL®
CA-630, 50 mM Tris⋅Cl [pH 8.0]), separated on the
SDS-PAGE and transferred to PVDF membrane (Milli-
pore, Billerica, MA, USA). The blots were incubated
with the indciated antibody. For control, the blot was
washed with stripping buffer (Thermo Scientific, Rock-
ford, IL, USA) and re-probed. Antibodies used in West-
ern blot analyses were as follows: anti-FLAG antibody
(M2, F1804, Sigma-Aldrich), anti-c-Myc-antibody (9E10,
M4493, Sigma-Aldrich), anti-Bcl-2 antibody (50E3,
#2870, Cell Signaling, Danvers, MA, USA), anti-Bcl-xL
antibody (54H6, #2764, Cell Signaling), anti-Mcl-1 anti-
body (#4572, Cell Signaling), anti-Bad antibody (#9292,
Cell Signaling), anti-Bax antibody (#2772, Cell Signal-
ing), anti-BID antibody (#2002, Cell Signaling), anti-
PAK1 polyclonal antibody (N-20, sc-882, SANTA CRUZ
Biotechnology), anti-phosphorylated PAK1 antibody
(Thr 423, sc-21903-R, SANTA CRUZ Biotechnology),
anti-ERK1/2 antibody (#9102, Cell Signaling), phosphor-
ylated ERK2 (Thr202/Tyr204, # 9101, Cell Signaling),
anti-tyrosine hydroxylase antibody (AB152, Millipore,
Billerica, MA, USA).
Ubiqutination assay
HEK cells were transfected with the indicated amount of
PAK1-DN or PAK1-CA plasmids, incubated for 36 h,
treated with 10 μM lactacystin (Tocris) for 12 h and sub-
jected to immunoprecipitation with anti-Bcl-2 antibody
(Cell Signaling). Immunoprecipitates were subjected to
Western blot analysis using anti-monoclonal mono- and
polyubiquitinylated conjugates antibody (FK2, BML-
PW8810, Enzo Life Sciences, Farmingdale, NY, USA).
Immunostaining
Cultured neurons were treated with 100 μM of 6-OHDA
for 9 h, fixed with 4 % paraformaldehyde solution. Im-
munocytochemistry was conducted as described in a
previous study [46]. For immunohistochemistry, anes-
thetized animals were dissected and fixed by vascular
perfusion with 4 % paraformaldehyde solution through
the heart. Total brain was isolated and additionally incu-
bated with 4 % paraformaldehyde solution for 24 h.
Then brain tissues were incubated with 20 % sucrose so-
lution for 36 – 48 h, mounted in OCT embedding com-
pound, frozen at −80 °C, and coronally cut into 30 μm
thick tissue sections by a cryostat (Leica 1650, Leica,
Wetzlar, Germany). Neuronal cultures and tissue sec-
tions were permeabilized with PBST (0.1 % Triton X-
100, 0.2 % BSA, 1X PBS, pH7.4), and blocked with a pre-
blocking agent (2 % BSA, 0.08 % Triton X-100, 1X PBS,
pH7.4). The cultures were treated with PAK1 or p-PAK1
antibody and visualized by secondary staining with Cy3-
conjugated goat anti-rabbit IgG antibody (111–165–144,
Jackson ImmunoResearch Laboratories, West Grove,
PA). Tissue sections were treated with anti-Tyrosine Hy-
droxylase antibody (Millipore) and subsequently immu-
nostained with Cy3-conjugated goat anti-rabbit IgG
antibody. Immunostained cells and tissue sections were
acquired by an up-right fluorescence microscope (BX-
51, Olympus, Tokyo, Japan) equipped with a CCD cam-
era (DP30BW, Olympus) and the images were analyzed
by NIH image analysis program (ImageJ ver 1.47v, Be-
thesda, MA, USA).
Phosphatase inhibitor assay
SH-SY5Y cells were pretreated with 200 nM Cantharidic
acid (Santa Cruz Biotechnology), 0.2 nM Cypermethrin
(Santa Cruz Biotechnology), or 0.5 nM Okadaic acid
(Sigma-Aldrich) for 30 min and treated along with 50
μM 6-OHDA for 8 h 30 min. The cell lysates were sub-
jected to Western blot analysis.
Stereotaxic surgical procedure
Adult female Sprague–Dawley rats (~230 g) were anes-
thetized by a subcutaneous injection of a Zoletil/Rom-
pun cocktail solution (5 mg/kg Zoletil 50, Virbac
Laboratories, Carros, France; 0.5 ml/kg Rompun, Bayer,
Berlin, Germany). Animals were placed into a stereotaxic
frame (ASI® Instruments, Warren, MI, USA). Burr holes
were drilled to allow a single unilateral injection of 6-
OHDA or a double injection of 6-OHDA or saline and
lentivirus. A 4 μl dose of 6-OHDA (5 μg/μl) was infused
into the right striatum at a rate of 0.5 μl/min at the fol-
lowing coordinates: anteroposterior, 1.0 mm from the
bregma; mediolateral, −3.0 mm; dorsoventral, −5.0 mm
below surface of the dura [27]. A 2 μl dose of lentivirus
encoding GFP or PAK1-CA (1–2 X107 TU/ml) was in-
fused into the right SNpc at a rate of 0.5 μl/min at the
following coordinates: anteroposterior, −5.3 mm from
the bregma; mediolateral, −2.3 mm; dorsoventral, −7.3 mm
below surface of the dura [27].
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Behavioral test (cylinder test)
A unilateral lesion of the nigrostriatal pathway was mea-
sured by examining the asymmetry in forelimb usage
[29, 30]. Experimental animals were placed in a transpar-
ent cylinder, 30 cm high and 20 cm in diameter, for 5
min. The contact with the wall by the impaired, unim-
paired or both forelimbs was scored and presented as
percentage. Animals which showed usage of the left or
right forelimb in a pretest up to more than 70 % were
excluded in subsequent experiments.
Statistical analysis
All data are presented as mean ± SEM. Statistical signifi-
cance between the two groups was measured by Student’s
t-tests and that among more than three groups by ANOVA
analysis with an appropriate post-hoc test. Statistical differ-
ence in cell viability induced by PAK1 and its mutants was
analyzed by one-way ANOVA and Newman-Keuls multiple
comparison test. Animal behavior was analyzed by two-way
ANOVA and Bonferroni multiple comparison test.
Ethics approval and consent to participate
All animal experiments were performed in accordance
with the approved animal protocols and the guidelines
of the Institutional Animal Care and Use Committee of




These results indicate the roles of PAK1 in neuronal
death and neurodegeneration induced by oxidative stress.
Down-regulation of PAK1 activity was strongly correlated
with cell death and loss of mesencephalic DA neurons.
Conversely, up-regulation of PAK1 activity recovered loss
of mesencephalic DA neurons and behavioral defects in a
hemiparkinsonian animal model. Taken together, our data
provided novel mechanisms in the pathogensis of PD and
a useful therapeutic target.
Availability of data and materials
The datasets supporting the conclusions of this article
are included within the article.
Additional files
Additional file 1: Figure S1. SH-SY5Y cells and HEK 293T cells
expressed endogenous PAK1. The 10 or 20 μg of lyastes from each cell
line was separated on SDS-PAGE and subjected to Western blot analysis
using anti-PAK1 antibody. The membrane was deprobed and reprobed
by anti-GAPDH antibody. (TIF 2426 kb)
Additional file 2: Figure S2. Reduction of Bcl-2 level by 6-OHDA treat-
ment is independent of transcription. a. SH-SY5Y cells were treated 50
μM 6-OHDA for 9 h and total RNA was isolated. Purified 3 μg of total
RNA was used in RT-PCR analysis for Bcl-2, Bcl-XL, and GAPDH mRNA
(w/o: negative control without RT reaction). b. Bar graphic representation
of RT-PCR analysis. The intensity of Bcl-2 or Bcl-XL band at each time point
was normalized by the intensity of GAPDH band, respectively. The data
was presented a relative value to value of 0 h. (TIF 163 kb)
Additional file 3: Figure S3. 6-OHDA treatment reduces
phosphorylated PAK1 level in cultured DA neurons. a. Mesencephalic DA
neurons were isolated from the ventral tegumental area (VTA) and
cultured for 16 day before use. Cultured DA neurons were treated with
100 μM 6-OHDA for 9 h and fixed. The cultures were immunostained
with anti-monoclonal tyrosine hydroxylase antibody (TH-16, T2928,
Sigma-Aldrich), anti-polyclonal PAK1 antibody (N-20, sc-882, SANTA CRUZ
Biotechnology), or anti-phospho-PAK1 antibody (sc-21903-R, SANTA CRUZ
Biotechnology). The cultures were subsequently immunostained with
Alex Fluor® 488 anti-mouse IgG antibody (A11029, Molecular Probes) for
visualization of TH staining and Cy3-conjugated anti-rabbit IgG antibody
(111–165–144, Jackson ImmunoResearch Lab) for PAK1 and p-PAK1
staining. Images were acquired by fluorescent microscopy (BX-51,
Olympus) and analyzed by NIH image analysis program (ImageJ ver
1.47v). Scale bar: 20 μm. b. Bar graphic representation of image analysis.
6-OHDA treatment could not change PAK1 level (CTL: 100.0 ± 7.40 %,
n = 55 neurons from 6 plates; 6-OHDA: 109.2 ± 3.79 %, n = 56 neurons
from 6 plates, ns: not significant) but decreased p-PAK1 level (CTL: 100.0 ±
5.56 %, n = 20 neurons from 3 plates; 6-OHDA: 72.71 ± 8.81 %, n = 27 neurons
from 3 plates, Student’s t-tests: * P< 0.05) (TIF 10356 kb)
Additional file 4: Figure S4. PAK1-DN expression reduces the Bcl-2
level in HEK 293T cells. a. Lysates of HEK 293T cells transfected with GFP,
PAK1-WT, PAK1-CA, or PAK1-DN vectors were subjected to Western blot
analysis using Bcl-2 antibody. b. Quantification of Western blot analysis.
Each band was normalized with the band intensity of WT (GFP: 101.0 ±
5.19 %, n = 5; WT: 100.0 %, n = 5; CA: 95.9 ± 6.46 %, n = 5; DN: 73.16 ± 6.87
%, n = 5; One-way ANOVA, F3,19 = 5.909,
**P = 0.0065, Newman-Keuls
multiple comparison test: **P < 0.01, *P <0.5). (TIF 2613 kb)
Additional file 5: Figure S5. Reduction of Bcl-1 by PAK-DN is
independent of transcription. a. Total RNA was purified from SH-SY5Y
cells expressing GFP, PAK1-CA, or PAK1-DN. And 3 μg of total RNA from
each was used for RT-PCR analysis using SuperScript III (Invitrogen). The
PCR primers used in RT-PCR are follows; Bcl-2 forward: 5′-agatgggaa-
cactggtggag-3′, Bcl-2 reverse: 5′-cttccccaaaagaaatgcaa-3′, Bad forward:
5′-cctcaggcctatgcaaaaag-3′, Bad reverse: 5′-taaacctggctcgcgactta-3′, Bcl-xL
forward: 5′-ggctgggatacttttgtgga-3′, Bcl-xL reverse: 5′-gggagggtagagtg-
gatggt-3′, GAPDH forward: 5′-gagtcaacggtttggtcgt-3′, GAPDH reverse:
5′-ttgattttggagggatctcg-3′. b. Bar graphic representation of RT-PCR
analysis. Each band was normalized with intensity of GAPDH. (TIF 208 kb)
Additional file 6: Figure S6. Other mutants of PAK1- inactive form
reduce Bcl-2 level. a. HEK cells were transfected with 1, 2, or 3 μg of GFP,
PAK1-WT, PAK1-H83,86L, or PAK1-K299R vectors and incubated for 48 h. The
cell lysates were subjected to Western blotting analysis using anti-Myc, Bcl-
2, Bcl-xL, or GAPDH antibody. b. The autoinhibitory domain (AID) of hPAK1
(67–150 amino acids) were amplified by PCR methods (hPAk1-67-R1-S: 5′-
ggaattcggaagaaagagaaagagcggc-3′, hPAK1-150-Xho-A: 5′-ccgctcgagttaagct
gacttatctgtaaagc-3′) and inserted to EcoRI/XhoI site of pCMV-Myc vector
(Clontech) in-frame with Myc-tag, producing PAK1-DN (67–150) [47]. HEK
cells were transfected with 1, 2, or 3 μg of PAK1-DN (67–150) vector and cell
lysates were analyzed by Western blotting assay. (TIF 278 kb)
Additional file 7: Figure S7. PAK1-CA expression rescues behavioral
defect and loss of mesencephalic dopamine neurons induced by MPTP
injection. a. Experimental scheme and procedure. b. Lentiviruses encoding
GFP or PAK1-CA were infused into the right SNpc at rate of 0.5 μl/min at the
following coordinates: anteroposterior, −5.3 mm from the bregma;
mediolateral, −2.3 mm; dorsoventral, −7.3 mm below surface of the dura. A 2
μl dose of MPTP-HCl (1 μM, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
hydrochloride, Sigma-Aldrich) was infused into the right striatum at a rate of
0.5 μl/min at the following coordinates: anteroposterior, 1.0 mm from the
bregma; mediolateral, −3.0 mm; dorsoventral, −5.0 mm below surface of the
dura [48]. After 3 weeks, the midbrain tissue sections were immunostained
with anti-Tyrosine Hyroxylase antibody and visualized by immunostaining
using Cy3-conjugated goat anti-rabbit IgG antibody. c. The loss of DA neurons
in the SNpc induced by MPTP injection was blocked by PAK1-CA expression,
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but not by GFP expression (GFP: 75.7 ± 0.41 %, n = 3, compared to the
ipsilateral side; PAK1-CA: 101.4 ± 2.71 %, n = 4, compare to ipsilateral side,
Student’s t-tests, **P< 0.01). d. PAK1-CA expression significantly improved
usage of the contralateral limb in a hemiparkinsonian animal model (GFP:
PAK1-CA, pretest, 48.8 ± 1.59, n = 3: 52.8 ± 1.92, n = 4; 1 week, 29.6 ± 2.50, n = 3:
44.03 ± 5.18, n = 4; 2 weeks, 34.2 ± 3.30, n = 3: 48.30 ± 2.58, n = 4; 3 weeks,
28.97 ± 1.09, n = 3: 45.75 ± 2.15, n = 4; Two-way ANOVA, F3, 20 = 1.746, P= 0.19,
1, Bonferroni multiple comparison tests, *P< 0.05, **P< 0.01). (TIF 2786 kb)
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